OABI / OmniAb: Legitimate Competition To AbCellera In Antibody Discovery

OmniAb is a long-term growth story. The company's Q2 earnings call reported nice growth in its projects and partners. As a newly formed company with l more_horizontal

OmniAb, Inc. (NASDAQ:OABI ) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Kurt Gustafson - CFO Matthew Foehr - Pres more_horizontal

OmniAb, Inc. (NASDAQ:OABI ) Q4 2022 Earnings Conference Call March 30, 2023 8:00 AM ET Company Participants Kurt Gustafson - CFO Matt Foehr - Presiden more_horizontal

OmniAb recently completed its separation from Ligand Pharmaceuticals and is now a publicly traded independent company solely focused on antibody disco more_horizontal

Analysts Say These Are Penny Stocks To Buy But Are They Worth The Risk? The post 5 Penny Stocks With Explosive Price Targets & Buy Ratings From Analys more_horizontal

It has been a rough start for antibody discovery biotech OmniAb (US:OABI) since listing via a SPAC merger with Avista Public Acquisition Corp (US:AHPA more_horizontal

OmniAb is an 11/2022 spinoff from Ligand Pharmaceuticals. The company has a highly differentiated and attractive business model. more_horizontal

Hot penny stocks to watch after October's CPI report. The post Best Penny Stocks To Buy Now That CPI Is Out? more_horizontal